Clinical Trials Logo

Eclampsia clinical trials

View clinical trials related to Eclampsia.

Filter by:

NCT ID: NCT05625763 Not yet recruiting - Pre-Eclampsia Clinical Trials

State of Coagulation in Pre-eclampsia: Comparing Sonoclot Signature Analysis With Conventional and Specific Haemostasis Assays

Start date: November 15, 2022
Phase:
Study type: Observational

- Detection of the presence or absence of coagulopathy in cases with pre-eclampsia. - Investigate the value of global hemostasis studies (Sonoclot signature analysis) in cases of pre-eclampsia and if there a correlation between it and the specific traditional assays of hemostasis.

NCT ID: NCT05625724 Recruiting - Pre-Eclampsia Clinical Trials

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology

APPART
Start date: August 2, 2023
Phase: Phase 3
Study type: Interventional

This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.

NCT ID: NCT05622838 Not yet recruiting - Pre-Eclampsia Clinical Trials

Maternal alpha1 Antitrypsin as a Marker of Intrauterine Growth Restriction in Pre-eclamptic Women

Start date: December 2022
Phase:
Study type: Observational

Intrauterine growth restriction (IUGR) is defined as a velocity of fetal growth less than the normal fetus growth potential for a specific neonate as per the race and gender. These neonates face many acute problems during peripartum and after birth .The causes of IUGR may be maternal, placental, fetal or genetic and also due to combination of any of these factors. Knowledge of etiologies of fetal growth restriction (FGR) is essential, so that future care can be targeted at prevention . It is apparent that FGR is primarily caused by placental dysfunction (PIH&PE), insufficiency that lead to reduced fetal growth overall. FGR is associated with lifelong burden of chronic diseases including metabolic, respiratory, cardiovascular and neurological deficits. Pre-eclampsia (PE) is diagnosed by the combined presentation of high blood pressure and proteinuria. New definitions also include maternal organ dysfunction, such as renal, liver, neurological or haematological complications, uteroplacental dysfunction, or FGR . In an attempt to correct fetus reduced supply the placenta release various cytokines and markers as Alpha-1 anti-trypsin (AAT). The Golgi apparatus secretes this cytokine in placental cytotrophoblast and blood vessels. AAT is antinflammatory antiprotease protective molecule. AAT rises during normal pregnancy. The suboptimal rise of AAT in pregnancy are liable for increased obstetrical complications like abortion, preterm labor. AAT levels were found decreased in placenta tissues from women with PE compared that of healthy women. Although AAT deficiency is associated with several pregnancy and placental disorders, little is known regarding AAT levels and PE .

NCT ID: NCT05558969 Recruiting - Clinical trials for Neuromuscular Blockade

The Effect of Magnesium Use in Reversal of Neuromuscular Block With Sugammadex

Start date: September 28, 2022
Phase: N/A
Study type: Interventional

Magnesium therapy used for seizure prophylaxis in patients with preeclampsia. Magnesium has been shown to prolong the effect of nondepolarizing neuromuscular blocking agents (NMBA) and neostigmine used to reverse the effect of NMBA in general anesthesia . In this study, the investigators aimed to evaluate time from sugammadex injection to Train-of-four ratio 0.9 who receieved magnesium therapy in reversing the effect of neuromuscular blocking agent during the recovery period and the relationship between magnesium level and duration of action of sugammadex

NCT ID: NCT05554185 Not yet recruiting - Clinical trials for PE (Pre-eclampsia) High-risk Population With Gut Microbiota Dysbiosis During Their Pregnancy

Probiotic Supplementation During Pregnancy in Preeclampsia High-risk Groups

Start date: September 21, 2022
Phase: N/A
Study type: Interventional

In this randomized controlled study, preventive intervention of aspirin combined with probiotics or aspirin combined with placebo would given to PE (pre-eclampsia) high-risk population with gut microbiota dysbiosis during their pregnancy, and finally assess the efficacy and safety of aspirin combined with probiotics to prevent PE.

NCT ID: NCT05542654 Completed - Pre-Eclampsia Clinical Trials

The Effect of Foot Massage on Blood Pressure and Anxiety Levels in Pregnants With Hypertension

Start date: November 5, 2020
Phase: N/A
Study type: Interventional

This research was conducted as a prospective, experimental and randomised controlled research to determine the effect of foot massage applied to pregnant women with hypertension on blood pressure and anxiety levels.

NCT ID: NCT05533996 Not yet recruiting - Clinical trials for Gestational Diabetes

Body Fat Index for Obstetric Risk Stratification

BFIors
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Primary Outcome:- GDM Diagnosis Secondary Outcomes:- Pre-eclampsia diagnosis. Cesarean section delivery due to labor dystocia defined as protracted or arrested progress of labor using labor partogram.

NCT ID: NCT05500989 Recruiting - Pregnancy Clinical Trials

PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis

PEARLS
Start date: November 2016
Phase:
Study type: Observational

Pregnancy is considered a cardiovascular (CV) stress test, and complicated pregnancies are associated with an increased risk for cardiovascular disease (CVD) later in life. Moreover, it is known that often the pregnancy induced CV adaptation does not resolve completely after a short postpartum (PP) period and it is not clear whether these induced changes will resolve over a longer period of time (i.e. in the upcoming months/years after delivery). Understanding the cardiac adaptation during pregnancy and the reversal process in the postpartum period, as well as the factors that influence this these processes, may provide us not only insight in this mechanism, but may help us in identifying factors that may be target points for modification.

NCT ID: NCT05470712 Completed - Pre-Eclampsia Clinical Trials

Vital Mechanism of NETs Formation vs. Suicidal Mechanism of NETs Formation During Normal Pregnancy and Preeclampsia

GrossNETs
Start date: July 20, 2022
Phase:
Study type: Observational

Formation of neutrophil extracellular traps (NETs) is a process of activation of neutrophils, which then generate filaments containing DNA, enzymes and extracellular histones. Two mechanisms of formation of NETs are described in the literature: vital mechanism via Toll Like Receptors (TLRs) and suicidal mechanism, dependent on the reactive oxygen species (ROS) pathway. The description of these two mechanisms of formation of NETs is recent and no data exist in the context of pregnancy.

NCT ID: NCT05460416 Not yet recruiting - Embryo Transfer Clinical Trials

Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer

TePPAFET
Start date: August 22, 2022
Phase: Phase 4
Study type: Interventional

Title: A prospective multicentric interventional randomized controlled trial to assess the effect of low dose acetylsalicylic acid as a preventive treatment of pre-eclampsia in pregnant women who underwent frozen embryo transfer